News
WXIBF
6.45
NaN%
--
Weekly Report: what happened at WXIBF last week (1019-1023)?
Weekly Report · 1d ago
Weekly Report: what happened at WXIBF last week (1012-1016)?
Weekly Report · 10/19 09:14
Beyond The AI Trade: Earnings, Infrastructure And A Broadening EM Opportunity
Seeking Alpha · 10/13 07:31
Weekly Report: what happened at WXIBF last week (1005-1009)?
Weekly Report · 10/12 09:15
Weekly Report: what happened at WXIBF last week (0928-1002)?
Weekly Report · 10/05 09:15
Weekly Report: what happened at WXIBF last week (0921-0925)?
Weekly Report · 09/28 09:14
Weekly Report: what happened at WXIBF last week (0914-0918)?
Weekly Report · 09/21 09:14
Morgan Stanley Remains a Buy on Wuxi Biologics (Cayman) (WXIBF)
TipRanks · 09/19 00:26
Guotai Haitong Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
TipRanks · 09/18 06:27
Weekly Report: what happened at WXIBF last week (0907-0911)?
Weekly Report · 09/14 09:15
Baron Emerging Markets Fund repositions portfolio with 4 new positions and7 exits
Seeking Alpha · 09/11 12:30
Weekly Report: what happened at WXIBF last week (0831-0904)?
Weekly Report · 09/07 09:14
Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Zhongtai Securities
TipRanks · 09/05 17:25
WuXi Biologics price target raised to HK$62 from HK$51.10 at UBS
TipRanks · 09/01 23:00
Weekly Report: what happened at WXIBF last week (0824-0828)?
Weekly Report · 08/31 09:15
CLSA Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
TipRanks · 08/29 00:28
Bank of America Securities Reaffirms Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)
TipRanks · 08/29 00:28
CICC Remains a Buy on Wuxi Biologics (Cayman) (WXIBF)
TipRanks · 08/28 05:17
Analysts Offer Insights on Healthcare Companies: Mesoblast Limited (OtherMEOBF), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Wuxi Biologics (Cayman) (OtherWXIBF)
TipRanks · 08/28 00:20
Jefferies Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
TipRanks · 08/27 12:18
More
Webull provides a variety of real-time WXIBF stock news. You can receive the latest news about Wuxi Bio through multiple platforms. This information may help you make smarter investment decisions.
About WXIBF
WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.